Hyperuricemia effect on clinical and immunological aspects of psoriatic arthritis
DOI: 10.32364/2587-6821-2025-9-3-2
I.Z. Gaydukova1,2, V.I. Mazurov1,2, O.V. Inamova1,2, M.S. Petrova1,2
1I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation
2V.A. Nasonova Clinical Rheumatology Hospital, St. Petersburg, Russian Federation
Background: regardless of many papers dedicated to hyperuricemia (HU) effect on the course of psoriatic arthritis (PsA), available data are hazy, and the issue of interest is still underinvestigated.
Aim: to evaluate an effect of hyperuricemia (HU) on clinical features of PsA.
Materials and Methods: based on the rheumatology registry of St. Petersburg (2005-2020), two groups of patients (HU patients with PsA (n=131), and non-HU ones with PsA (n=130)) were formed and retrospectively analyzed. HU was recorded at a blood uric acid (UA) level of >360 mmol/l in ≥2 tests ≥1 month apart in the absence of gouty arthritis.
Results: the patients were comparable in age and gender. In non-HU patients, the onset of polyarthritis (variant 2) was reported at the age of 60.53±10.35, and those with oligoarthritis or monoarthritis of the joints of the lower extremities/spine (variant 1) demonstrated its onset at the age of 48.64±13.36 (p<0.001). Along with this, the onset of variant 1 was significantly more common (p<0.001) in men than in women (84% vs. 67.86%, respectively), and the variant 2 was more common in women than in men (32.14% vs. 16%, respectively). HU patients demonstrated higher incidence of scalp and nail lesions (41.54% vs. 26.71%; p<0.01). Although the patients received comparable therapy, HU subjects were more likely to receive leflunomide (10% vs. 3.05%, respectively).
Conclusions: in patients with PsA, HU is associated with an increased incidence of scalp and nail psoriasis. Both polyarthritic and monooligoarthritic variants of PsA onset are equally common in HU patients. They were more likely to receive leflunomide, and the fact is impliedly consistent with more severe course of PsA associated with HU.
Keywords: hyperuricemia, uric acid, psoriasis, psoriatic arthritis, genetically engineered biological therapy.
For citation: Gaydukova I.Z., Mazurov V.I., Inamova O.V., Petrova M.S. Hyperuricemia effect on clinical and immunological aspects of psoriatic arthritis. Russian Medical Inquiry. 2025;9(3):156–161 (in Russ.). DOI: 10.32364/2587-6821-2025-9-3-2
About the authors:
Alexandra Yu. Tsinserling — C. Sc. (Med.), rheumatologist, V.A. Nasonova Clinical Rheumatology Hospital; 30, Bolshaya Podyacheskaya str., St. Petersburg, 190068, Russian Federation; ORCID iD 0000-0003-4860-0518
Inna Z. Gaydukova — Dr. Sc. (Med.), Deputy Director of the Research Institute of Rheumatology, Professor of the Department of Internal Medicine, Rheumatology, Examination of Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, I.I. Mechnikov North-Western State Medical University; 41, Kirochnaya str., St. Petersburg, 191015, Russian Federation; V.A. Nasonova Clinical Rheumatology Hospital; 30, Bolshaya Podyacheskaya str., St. Petersburg, 190068, Russian Federation; ORCID iD 0000- 0003-3500-7256
Vadim I. Mazurov — Dr. Sc. (Med.), Academician of the Russian Academy of Sciences, Honored Scientist of the Russian Federation, Professor, Chief Scientific Consultant, Director of the Research Institute of Rheumatology, Head of the Department of Therapy, Rheumatology, Examination of Temporary Disability and Quality of Medical Care with a course in Hematology and Transfusiology named after E.E. Eichwald, North West State Medical University named
after I.I.Mechnikov; 41, Kirochnaya str., St. Petersburg, 191015, Russian Federation; ORCID iD 0000-0002-0797-2051
Oksana V. Inamova — C. Sc. (Med.), Chief Medical Officer of the V.A. Nasonova Clinical Rheumatology Hospital; 30, Bolshaya Podyacheskskaya str., St. Petersburg, 190068, Russian Federation; Deputy Director for Work with Clinical Bases of the Research Institute of Rheumatology, I.I. Mechnikov North-Western State Medical University; Assistant Professor of the Department of Therapy, Rheumatology, Examination of Temporary Disability and Quality of Medical Care named after E.E. Eichwald, I.I. Mechnikov North-Western State Medical University; 41, Kirochnaya str., St. Petersburg, 191015, Russian Federation; ORCID iD 0000-0001-9126-3639
Marianna S. Petrova — C. Sc. (Med.), Chief Medical Officer, Head of the City Clinical Center for Gout, V.A. Nasonova Clinical Rheumatology Hospital; 30, Bolshaya Podyacheskaya str., St. Petersburg, 190068, Russian Federation; Associate Professor of the Department of Therapy, Rheumatology, Examination of Temporary Disability and Quality of Medical Care named after E.E. Eichwald, I.I. Mechnikov North-Western State Medical University; 41, Kirochnaya str., St. Petersburg, 191015, Russian Federation; ORCID iD 0000-0001-5261-6614
Contact information: Alexandra Yu. Tsinserling, e-mail: aleksa.fonturenko@mail.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 10.02.2025.
Revised 05.03.2025.
Accepted 28.03.2025.
2. Bruce I.N., Schentag C.T., Gladman D.D. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol. 2000;6(1):6–9. PMID: 19078442
3. AlJohani R., Polachek A., Yang Y.J. et al. Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. J Rheumatol. 2018;45(2):213–217. DOI: 10.3899/jrheum.170384
4. Lai T.L., Yim C.W., Wong P.Y. et al. Hyperuricemia in Asian psoriatic arthritis patients. Int J Rheum Dis. 2018;21(4):843–849. DOI: 10.1111/1756-185X.13265
5. Felten R., Widawski L., Spielmann L. et al. Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies. RMD Open. 2023;9(4):e003428. DOI: 10.1136/rmdopen-2023-003428
6. Moshrif A., Mosallam A., Mohamed E.E. et al. Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study. Eur J Rheumatol. 2017;4(1):24–28. DOI: 10.5152/eurjrheum.2017.16049
7. Widawski L., Fabacher T., Spielmann L. et al. Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat. Clin Rheumatol. 2022;41(5):1421–1429. DOI: 10.1007/s10067-022-06061-x
8. Herrmann F. Harnsaureuntersuchungen bei Psoriasis. Archiv fur Dermatologie und Syphilis. 1930;161:114–126.
9. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R. et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. J Semin Arthritis Rheum. 2009;39(3):157–162. DOI: 10.1016/j.semarthrit.2008.06.001
10. Tsuruta N., Imafuku S., Narisawa Y. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol. 2017;44(12):1349–1352. DOI: 10.1111/1346-8138.13968
11. Menis J., Doussiere M., Touboul E. et al. Current characteristics of a population of psoriatic arthritis and gender disparities. J Clin Transl Res. 2023;9(2):84–92. PMID: 37034001
12. Kamiya K., Ohtsuki M. Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020. J Dermatol. 2023;50(1):12–25. DOI: 10.1111/1346-8138.16603
13. Queiro R., Cañete J.D. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association? Clin Rheumatol. 2018;37(3):661–666. DOI: 10.1007/s10067-018-4004-7
14. Dehlin M., Fasth A.E.R., Reinhardt M. et al. Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis-a post-hoc analysis of pooled data from three phase 3 trials with secukinumab. Rheumatol Adv Pract. 2021;5(1):rkab009. DOI: 10.1093/rap/rkab009
15. Zünkler B., Röber J. Early clinical screening in psoriatic arthropathy. Z Orthop Ihre Grenzgeb. 2000;138(4):360–368. DOI: 10.1055/s-2000-10163
16. Hernández-Collazo A.A., Villanueva-Quintero G., Rodríguez-Castellanos M.A. et al. Ácido úrico sérico como marcador De gravedad clínica y comorbilidad en psoriasis en placas. Gac Med Mex. 2018;154(4):427–431. DOI: 10.24875/GMM.17003515
17. Martinon F., Pétrilli V., Mayor A. et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. DOI: 10.1038/nature04516
18. Dai X.J., Tao J.H., Fang X. et al. Changes of Treg/Th17 Ratio in Spleen of Acute Gouty Arthritis Rat Induced by MSU Crystals. Inflammation. 2018;41(5):1955–1964. DOI: 10.1007/s10753-018-0839-y
19. Tripolino C., Ciaffi J., Ruscitti P. et al. Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications. Front Med (Lausanne). 2021;8:737573. DOI: 10.3389/fmed.2021.737573
20. Choe J.Y., Kim S.K. Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. Clin Chim Acta. 2015;438:29–34. DOI: 10.1016/j.cca.2014.07.039
21. Smoleńska Z., Kaznowska Z., Zarówny D. et al. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford). 1999;38(10):997–1002. DOI: 10.1093/rheumatology/38.10.997
22. Gosselt H.R., Muller I.B., Jansen G. et al. Identification of Metabolic Biomarkers in Relation to Methotrexate Response in Early Rheumatoid Arthritis. J Pers Med. 2020;10(4):271. DOI: 10.3390/jpm10040271
23. Costa N.T., Scavuzzi B.M., Iriyoda T.M.V. et al. Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. Clin Exp Med. 2018;18(3):363–372. DOI: 10.1007/s10238-018-0500-y
24. Perez-Ruiz F. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. J Clin Rheumatol. 2003;9(4):215–218. DOI: 10.1097/01.rhu.0000081470.31167.8b
25. Chen Z., Tu S., Hu Y. et al. Prediction of response of collagen-induced arthritis rats to methotrexate: an (1)H-NMR-based urine metabolomic analysis. J Huazhong Univ Sci Technolog Med Sci. 2012;32(3):438–443. DOI: 10.1007/s11596-012-0076-9
26. Lee J.J., Bykerk V.P., Dresser G.K. et al. Reduction in serum uric acid may be related to methotrexate efficacy in early rheumatoid arthritis: data from the Canadian Early Arthritis Cohort (CATCH). Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:37–43. DOI: 10.4137/CMAMD.S38092
27. Hasikova L., Pavlikova M., Hulejova H. et al. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. J Rheumatol Int. 2019;39(10):1749–1757. DOI: 10.1007/s00296-019-04394-6
28. Hagino T., Saeki H., Fujimoto E. et al. Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. J Clin Med. 2023;12(5):1934. DOI: 10.3390/jcm12051934
29. Tamer F., Edek Y.C., Aksakal A.B. Does biological agent treatment have an impact on serum uric acid levels in patients with psoriasis? Curr Med Res Opin. 2023;39(10):1297–1302. DOI: 10.1080/03007995.2023.2260304
30. Российские клинические рекомендации. Ревматология. Под ред. акад. РАН Насонова Е.Л. М.: ГЭОТАР-Медиа; 2017.Russian clinical guidelines. Rheumatology. Academician of the Russian Academy of Sciences E.L. Nasonov, ed. M.: GEOTAR-Media; 2017 (in Russ.).
31. Коротаева Т.В., Корсакова Ю.Л. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60–69. DOI: 10.14412/1995-4484-2018-60-69Korotaeva T.V., Korsakova Yu.L. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Rheumatology Science and Practice. 2018;56(1):60–69 (in Russ.). DOI: 10.14412/1995-4484-2018-60-69
32. Голов К.Г., Иванов О.Л., Балкаров И.М. Клиническое значение гиперурикемии при псориазе. Клиническая медицина. 1994;72(3):34–36.Golov K.G., Ivanov O.L., Balkarov I.M. et al. Clinical significance of hyperuricemia in psoriasis. Klin Med (Mosk). 1994;72(3):34–36 (in Russ.).
33. Бадокин В.В., Трошкина И.А., Александрова Е.Н. Ревматоидный фактор и антитела к циклическому цитруллинированному пептиду у больных с псориатическим артритом. Научно-практическая ревматология. 2011;49(5):32–37. DOI: 10.14412/1995-4484-2011-1458Badokin V.V., Troshkina I.A., Alexandrova E.N. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis. Rheumatology Science and Practice. 2011;49(5):32–37 (in Russ.). DOI: 10.14412/1995-4484-2011-1458
This work is licensed under a Creative Commons «Attribution» 4.0 License.
